Syremis Therapeutics
PrivateLast Round
Series A
Dec 18, 2025
Total Funding Raised
$165M
Company Overview
Syremis Therapeutics is a biopharmaceutical company that develops novel medicines for mental health disorders such as schizophrenia, major depressive disorder, and bipolar depression.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Mental Health, Clinical Trials
Business Model
B2B2C
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Syremis Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Syremis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 18, 2025 |
Syremis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bain Capital Life Sciences | Series A |
| Pictet Group | Series A |
| GV | Series A |
| QVT Financial | Series A |
| Third Rock Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 18, 2025
$165M Series A round completed.
Syremis Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Syremis Therapeutics's valuation, stock price, and market status.
